Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas.
We examined the expression of basic fibroblast growth factor (FGF) and FGF receptor by immunohistochemistry in 32 human pancreatic ductal adenocarcinomas. Mild to marked basic FGF immunoreactivity was noted in 19 (59.4%) of the 32 tumours examined, and 30 (93.3%) of the tumours exhibited a cytoplasmic staining pattern against FGF receptor. The tumours were divided into two groups according to the proportion of positively stained tumour cells: a low expression group (positive cells < 25%) and a high expression group (positive cells > or = 25%). No statistically significant difference in tumour size, differentiation, metastases or stage was found between the low and high basic FGF expression groups. However, a significant correlation was found between FGF receptor expression level and the presence of retroperitoneal invasion, lymph node metastasis, and tumour stage. In addition, low FGF receptor expression was significantly associated with a longer post-operative survival as compared with high FGF receptor expression, whereas there was no significant difference in post-operative survival between the low and high basic FGF expression groups. Increased expression of FGF receptor is correlated with the extent of malignancy and post-operative survival in human pancreatic ductal adenocarcinomas. Thus, overexpression of FGF receptor may prove to be a more useful prognostic marker than basic FGF expression level in pancreatic cancer patients.
Ohta
T
T
Department of Surgery (II), School of Medicine, Kanazawa University, Japan.
Yamamoto
M
M
Numata
M
M
Iseki
S
S
Tsukioka
Y
Y
Miyashita
T
T
Kayahara
M
M
Nagakawa
T
T
Miyazaki
I
I
Nishikawa
K
K
Yoshitake
Y
Y
D000328:Adult; D000368:Aged; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry* / Q000473:pathology; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008297:Male; D016253:Microscopy, Immunoelectron; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000737:chemistry* / Q000473:pathology; D011379:Prognosis; D017468:Receptors, Fibroblast Growth Factor / Q000032:analysis*
D017468:Receptors, Fibroblast Growth Factor; D016222:Fibroblast Growth Factor 2